Meeting
2023 ASCO Annual Meeting
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
Authors
Heather L. McArthur
University of Texas Southwestern Medical Center, Dallas, TX
Heather L. McArthur , Jorge Leal , Stephen Lawrence Shiao , Meredith Carter , Reva K Basho , Michelle Phillips , David Chan , Hugo Hool , Dorothy J. Park , Mary El-Masry , Philomena McAndrew , Swati Sikaria , Laura Spring , Aditya Bardia , Mourad Tighiouart , Farnaz Dadmanesh , Armando E. Giuliano , Katherine Sanchez , David B. Page
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT03747120
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS634)
DOI
10.1200/JCO.2023.41.16_suppl.TPS634
Abstract #
TPS634
Poster Bd #
454b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.
First Author: Heather L. McArthur
Poster
2022 ASCO Annual Meeting
Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.
First Author: Nan Niu
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2021 ASCO Annual Meeting
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
First Author: Giampaolo Bianchini